Recent medical advancements cover emerging weight-loss drug concerns, new Parkinson's treatment prospects, and clinical risks in aging populations.

The 2026 ADA Scientific Sessions highlighted concerns regarding muscle loss during GLP-1 therapy, prompting expert calls for better patient counseling and risk assessment.

Clinicians are navigating a surge in patients using unapproved weight-loss drugs like retatrutide, largely driven by viral trends on social media platforms.

A study in obese mice indicates that whole-plant cannabis extract may be more effective than isolated THC in improving glucose control metrics.

Tavapadon is currently under review as a potential breakthrough, representing the first new dopamine agonist treatment for Parkinson's disease in several decades.

Healthcare providers are being warned about prescribing cascades in older adults, where side effects of common medications lead to the unnecessary addition of further drugs.

Clinical research has determined that combining atezolizumab with stereotactic body radiotherapy (SBRT) for inoperable non-small cell lung cancer increases toxicity without improving survival.

A new narrative review suggests a U-shaped correlation between testosterone levels and atrial fibrillation risk in men, indicating that both high and low levels may be problematic.

Changing climate patterns are causing earlier pollen seasons, leading to an earlier onset of seasonal allergies and a shift in typical patient demand for relief treatments.